MCID: HMT002
MIFTS: 63

Hematologic Cancer

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Hematologic Cancer

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 38 12 55 15
Hematologic Neoplasm 12 29 6
Hematologic Malignancy 12 6
Hematologic Neoplasms 44 73
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematologic Malignancies 55
Hematopoietic Neoplasms 73
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2531
MeSH 44 D019337
NCIt 50 C27134
SNOMED-CT 68 414388001 414644002

Summaries for Hematologic Cancer

Disease Ontology : 12 An immune system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasm, is related to platelet disorder, familial, with associated myeloid malignancy and bone marrow cancer. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Endometrial cancer. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include the hematological system, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 platelet disorder, familial, with associated myeloid malignancy 33.7 ETV6 RUNX1
2 bone marrow cancer 33.5 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
3 myeloproliferative neoplasm 33.3 ABL1 JAK2 KIT MPL
4 mast cell neoplasm 33.2 IL2 IL3 KIT
5 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.1 ETV6 FLT3 KIT KMT2A RUNX1
6 leukemia 31.6 ABL1 CSF2 ETV6 FLT3 JAK2 KIT
7 myeloid leukemia 31.5 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
8 leukemia, acute myeloid 31.5 ABL1 CCDC26 CSF2 ETV6 FLT3 IL2
9 refractory hematologic cancer 12.3
10 central nervous system hematologic cancer 12.2
11 myeloproliferative/lymphoproliferative neoplasms, familial 11.6
12 chronic myelomonocytic leukemia 11.5 ETV6 FLT3 JAK2 KIT RUNX1
13 core binding factor acute myeloid leukemia 11.5 CBL FLT3 JAK2 KIT RUNX1 WT1
14 leukemia, chronic myeloid 11.5 ABL1 CBL CSF2 ETV6 FLT3 IL3
15 myelodysplastic syndrome 11.5 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
16 acute leukemia 11.5 ETV6 FLT3 IL3 JAK2 KIT KMT2A
17 leukemia, acute lymphoblastic 3 11.5 ABL1 ETV6 FLT3 KMT2A RUNX1
18 lymphoid leukemia 11.5 ETV6 FLT3 JAK2 KMT2A
19 precursor t-cell acute lymphoblastic leukemia 11.5 ABL1 ETV6 FLT3 KMT2A MLLT10 NUP98
20 lymphoblastic leukemia 11.5 ABL1 ETV6 FLT3 IL2 JAK2 RUNX1
21 refractory anemia 11.5 IL3 JAK2 MPL RUNX1
22 acute myeloid leukemia with t(8;21)(q22;q22) translocation 11.5 FLT3 KIT RUNX1
23 leukemia, acute lymphoblastic 11.5 ABL1 ETV6 FLT3 KMT2A RUNX1
24 chronic eosinophilic leukemia 11.5 ABL1 FLT3 KIT WT1
25 neutrophilia, hereditary 11.5 CSF2 FLT3 JAK2 PTHLH
26 polycythemia vera 11.5 ABL1 IL3 JAK2 KIT MPL
27 renal cell carcinoma, nonpapillary 11.5 CSF2 FLT3 IL2 KIT PTHLH PVT1
28 acute lymphocytic leukemia 11.5 CSF2 ETV6 IL2 RUNX1 XIST
29 juvenile myelomonocytic leukemia 11.5 CBL CSF2 FLT3 JAK2 RUNX1
30 myelofibrosis 11.4 FLT3 IL3 JAK2 KIT MPL
31 childhood leukemia 11.4 ABL1 ETV6 KMT2A RUNX1
32 leukocyte disease 11.4 CSF2 IL2 IL3 KIT
33 thrombocytosis 11.4 CSF2 IL3 JAK2 MPL
34 lymphoma, hodgkin, classic 11.4 CSF2 IL2 IL3 PVT1
35 mn1 11.4 ETV6 FLT3 KMT2A
36 cytogenetically normal acute myeloid leukemia 11.4 FLT3 KMT2A WT1
37 megakaryocytic leukemia 11.4 CSF2 IL3 JAK2 RUNX1
38 hypereosinophilic syndrome, idiopathic 11.4 IL3 KIT WT1
39 congenital mesoblastic nephroma 11.4 ETV6 KIT WT1
40 8p11 myeloproliferative syndrome 11.4 FLT3 KIT RUNX1
41 severe congenital neutropenia 11.4 CSF2 IL3 JAK2 RUNX1
42 immune system disease 11.4 CSF2 IL2 IL3 JAK2
43 hypereosinophilic syndrome 11.4 ABL1 CSF2 IL3 KIT
44 aplastic anemia 11.4 CSF2 FLT3 IL2 IL3 MPL
45 myeloid sarcoma 11.4 FLT3 KIT KMT2A
46 acute promyelocytic leukemia 11.4 FLT3 IL3 PVT1 RUNX1 WT1
47 dysgerminoma of ovary 11.4 KIT PTHLH WT1
48 atypical chronic myeloid leukemia 11.4 ABL1 JAK2 RUNX1
49 malignant mesenchymoma 11.4 ETV6 KIT WT1
50 leukemia, acute monocytic 11.3 KMT2A MLLT10 NUP98

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.4 FLT3 KIT IL2 JAK2 CBL ETV6
2 growth/size/body region MP:0005378 10.39 KIT IL2 JAK2 FLT3 ENG CBL
3 hematopoietic system MP:0005397 10.37 KIT IL2 JAK2 FLT3 ENG CBL
4 homeostasis/metabolism MP:0005376 10.32 FLT3 KIT IL2 ETV6 JAK2 ENG
5 cardiovascular system MP:0005385 10.31 KIT IL2 ETV6 ENG CBL CSF2
6 immune system MP:0005387 10.3 FLT3 KIT IL2 JAK2 CBL ETV6
7 embryo MP:0005380 10.28 KIT ETV6 JAK2 ENG CSF2 ABL1
8 endocrine/exocrine gland MP:0005379 10.26 FLT3 KIT IL2 ETV6 JAK2 CBL
9 mortality/aging MP:0010768 10.24 FLT3 KIT IL2 ETV6 JAK2 ENG
10 craniofacial MP:0005382 10.09 CSF2 ABL1 ENG CBL PTHLH KMT2A
11 integument MP:0010771 10.09 JAK2 KIT ETV6 ENG CBL CSF2
12 liver/biliary system MP:0005370 10.01 JAK2 KIT IL2 CBL ABL1 KMT2A
13 neoplasm MP:0002006 9.97 FLT3 KIT IL2 JAK2 ETV6 CSF2
14 no phenotypic analysis MP:0003012 9.8 FLT3 IL2 ETV6 KMT2A KIT WT1
15 normal MP:0002873 9.76 JAK2 ETV6 ABL1 ENG KMT2A KIT
16 respiratory system MP:0005388 9.61 KIT IL2 ENG CBL CSF2 ABL1
17 skeleton MP:0005390 9.28 JAK2 FLT3 ABL1 CBL CSF2 PTHLH

Drugs & Therapeutics for Hematologic Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
3
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 508)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
6
Protein C Approved Phase 4,Phase 2
7
Caspofungin Approved Phase 4,Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
8
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
9
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
24 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
25 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
27 Drotrecogin alfa activated Phase 4
28 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Not Applicable
30 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 1,Not Applicable
31 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Echinocandins Phase 4,Phase 2
33
Hydroxyitraconazole Phase 4
34 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
37 interferons Phase 4,Phase 3,Phase 2,Phase 1
38 Mitogens Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 55-98-1 2478
40
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
41
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
42
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
43
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
44
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
45
Vidarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
46
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
47
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
48
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
49
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
50
deoxycholic acid Approved Phase 3 83-44-3 222528

Interventional clinical trials:

(show top 50) (show all 863)
# Name Status NCT ID Phase Drugs
1 A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM) Completed NCT02966457 Phase 4 Colistimethate Sodium
2 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Completed NCT02895529 Phase 4 Itraconazole;Caspofungin
5 Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT Recruiting NCT02634294 Phase 4 Peg interferon alfa-2b
6 HPV Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation Recruiting NCT03023631 Phase 4
7 SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients Terminated NCT01222819 Phase 4 filgrastim
8 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
9 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
10 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
11 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
12 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
13 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
14 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
15 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
16 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
17 Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Completed NCT01767467 Phase 3 Placebo
18 Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed NCT00044759 Phase 3 Piperacillin/Tazobactam (Tazocin)
19 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3
20 Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens Completed NCT02635984 Phase 3 Olanzapine;Placebo
21 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
22 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients Completed NCT00824993 Phase 3 Ibandronate;Vitamin Supplements
23 Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy Completed NCT01435200 Phase 3 Intravenous iron
24 Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01237639 Phase 3
25 A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Completed NCT00300664 Phase 2, Phase 3 Human Growth hormone
26 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
27 Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection Completed NCT01032408 Phase 3
28 INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant Completed NCT01602211 Phase 3
29 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed NCT00750737 Phase 3 Posaconazole;ABLC
30 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
31 A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients Completed NCT01769170 Phase 3 Brincidofovir (CMX001)
32 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
33 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Completed NCT01568866 Phase 3 Carfilzomib;Bortezomib;Dexamethasone
34 Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3 doxepin hydrochloride oral solution;DLA (diphenhydramine, lidocaine and antacids) rinse
35 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Completed NCT02116530 Phase 3 Olanzapine;Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
36 Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed NCT01080391 Phase 3 Dexamethasone;Lenalidomide;Carfilzomib
37 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3 Thalidomide;Dexamethasone
38 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
39 PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00048230 Phase 3 bortezomib
40 Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) Completed NCT01410227 Phase 3 Placebo
41 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
42 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
43 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
44 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
45 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
46 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
47 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
48 TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia Recruiting NCT03136445 Phase 3 Tranexamic acid (TXA).;Placebo
49 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Recruiting NCT02178683 Phase 3 Tacrolimus and MMF.
50 Platelet Transfusion Requirements in Hematopoietic Transplantation Recruiting NCT02650791 Phase 3 Tranexamic Acid

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 23711284 21277377
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

# Genetic test Affiliating Genes
1 Hematologic Neoplasm 29

Anatomical Context for Hematologic Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Hematologic Cancer:

19
The Hematological System

MalaCards organs/tissues related to Hematologic Cancer:

41
Bone, Bone Marrow, T Cells, Lung, Breast, Myeloid, B Cells

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show top 50) (show all 60)
# Title Authors Year
1
Clinical characteristics of disseminated intravascular coagulation in patients with solid and hematological cancers. ( 29703488 )
2018
2
Pre- and post-diagnosis physical activity, television viewing, and mortality among hematologic cancer survivors. ( 29385194 )
2018
3
Feasibility and preliminary efficacy of an exercise telephone counseling intervention for hematologic cancer survivors: a phase II randomized controlled trial. ( 29411314 )
2018
4
Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. ( 28919347 )
2017
5
Psychological distress, chronic conditions and quality of life in elderly hematologic cancer patients: study protocol of a prospective study. ( 29070033 )
2017
6
Childhood hematologic cancer and residential proximity to oil and gas development. ( 28199334 )
2017
7
Body Image Discomfort of Adolescent and Young Adult Hematologic Cancer Survivors. ( 28112547 )
2017
8
The association between methionine synthase A2756G polymorphism and hematological cancer: A meta-analysis. ( 29310321 )
2017
9
Correlates of meeting the combined and independent aerobic and strength exercise guidelines in hematologic cancer survivors. ( 28351397 )
2017
10
Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. ( 28778967 )
2017
11
Living with hematologic cancer: Recommendations, solutions. ( 28696193 )
2017
12
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. ( 27007053 )
2016
13
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. ( 27330573 )
2016
14
Understanding strength exercise intentions and behavior in hematologic cancer survivors: an analysis of the intention-behavior gap. ( 27052642 )
2016
15
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. ( 27400009 )
2016
16
Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? ( 27282880 )
2016
17
Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. ( 26763882 )
2016
18
Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners. ( 27987096 )
2016
19
Survivorship Care Plans and Treatment Summaries a8"in Adult Patients With Hematologic Cancer: a8"An Integrative Literature Review. ( 25901380 )
2015
20
Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. ( 26310541 )
2015
21
Cancer Care Burden among Primary Family Caregivers of Iranian Hematologic Cancer Patients. ( 26225701 )
2015
22
TET proteins and 5-methylcytosine oxidation in hematological cancers. ( 25510268 )
2015
23
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia. ( 26533739 )
2015
24
Hospitalization risk according to geriatric assessment and laboratory parameters in elderly hematologic cancer patients. ( 25684525 )
2015
25
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B for Primary Therapy of Invasive Aspergillosis among High-Risk Hematologic Cancer Patients in Brazil. ( 26534377 )
2015
26
The falling incidence of hematologic cancer after heart transplantation. ( 25100534 )
2014
27
The microfluidic multitrap nanophysiometer for hematologic cancer cell characterization reveals temporal sensitivity of the calcein-AM efflux assay. ( 24873950 )
2014
28
Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia. ( 25193462 )
2014
29
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. ( 24813251 )
2014
30
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. ( 24645687 )
2014
31
Evaluation of MycAssaya8c Aspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. ( 23620764 )
2013
32
Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients. ( 22565413 )
2013
33
Confirmation of the reported association of clonal chromosomal mosaicism with an increased risk of incident hematologic cancer. ( 23533652 )
2013
34
Xist RNA is a potent suppressor of hematologic cancer in mice. ( 23415223 )
2013
35
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. ( 22099500 )
2012
36
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. ( 22622039 )
2012
37
p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis. ( 23029260 )
2012
38
Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis. ( 22166040 )
2012
39
Physical activity and hematologic cancer prevention. ( 21113763 )
2011
40
Improving access to information and support for patients with less common cancers: hematologic cancer patients' views about Web-based approaches. ( 22189354 )
2011
41
Evolving information priorities of hematologic cancer survivors, caregivers, and other relatives. ( 20119694 )
2010
42
Mesial temporal sclerosis as a complication of hematologic cancer. ( 19434437 )
2009
43
Managed care considerations: hematologic cancer as a chronic disease. ( 19119536 )
2008
44
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. ( 18344563 )
2008
45
Phase 3 trials suggest ways to improve current hematologic cancer therapies. ( 18252877 )
2008
46
Femoral resurfacing in young patients with hematologic cancer and osteonecrosis. ( 18679763 )
2008
47
Posaconazole prophylaxis in hematologic cancer. ( 17526089 )
2007
48
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. ( 17607669 )
2007
49
Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy. ( 17516403 )
2007
50
Posaconazole prophylaxis in hematologic cancer. ( 17526091 )
2007

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

6
(show all 30)
# Gene Variation Type Significance SNP ID Assembly Location
1 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs267606706 GRCh37 Chromosome 11, 119148891: 119148891
2 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs267606706 GRCh38 Chromosome 11, 119278181: 119278181
3 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
4 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
5 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
6 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
7 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
8 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh38 Chromosome 4, 54728055: 54728055
9 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic rs121913615 GRCh37 Chromosome 1, 43815009: 43815009
10 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic rs121913615 GRCh38 Chromosome 1, 43349338: 43349338
11 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh37 Chromosome 11, 119148930: 119148930
12 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh38 Chromosome 11, 119278220: 119278220
13 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh38 Chromosome 12, 11869601: 11869601
14 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh37 Chromosome 12, 12022535: 12022535
15 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh38 Chromosome 12, 11884541: 11884541
16 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh37 Chromosome 12, 12037475: 12037475
17 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh37 Chromosome 12, 12038902: 12038902
18 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh38 Chromosome 12, 11885968: 11885968
19 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh37 Chromosome 5, 149441328: 149441328
20 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh38 Chromosome 5, 150061765: 150061765
21 CSF1R NM_005211.3(CSF1R): c.2906A> T (p.Tyr969Phe) single nucleotide variant Likely pathogenic rs1801271 GRCh37 Chromosome 5, 149433645: 149433645
22 CSF1R NM_005211.3(CSF1R): c.2906A> T (p.Tyr969Phe) single nucleotide variant Likely pathogenic rs1801271 GRCh38 Chromosome 5, 150054082: 150054082
23 CSF1R NM_005211.3(CSF1R): c.2906A> G (p.Tyr969Cys) single nucleotide variant Likely pathogenic rs1801271 GRCh37 Chromosome 5, 149433645: 149433645
24 CSF1R NM_005211.3(CSF1R): c.2906A> G (p.Tyr969Cys) single nucleotide variant Likely pathogenic rs1801271 GRCh38 Chromosome 5, 150054082: 150054082
25 CSF1R NM_005211.3(CSF1R): c.2905T> C (p.Tyr969His) single nucleotide variant Likely pathogenic rs121913393 GRCh37 Chromosome 5, 149433646: 149433646
26 CSF1R NM_005211.3(CSF1R): c.2905T> C (p.Tyr969His) single nucleotide variant Likely pathogenic rs121913393 GRCh38 Chromosome 5, 150054083: 150054083
27 CSF1R NM_005211.3(CSF1R): c.902T> C (p.Leu301Ser) single nucleotide variant Likely pathogenic rs121913390 GRCh37 Chromosome 5, 149453044: 149453044
28 CSF1R NM_005211.3(CSF1R): c.902T> C (p.Leu301Ser) single nucleotide variant Likely pathogenic rs121913390 GRCh38 Chromosome 5, 150073481: 150073481
29 CSF1R NM_005211.3(CSF1R): c.903G> T (p.Leu301Phe) single nucleotide variant Likely pathogenic rs1057520014 GRCh37 Chromosome 5, 149453043: 149453043
30 CSF1R NM_005211.3(CSF1R): c.903G> T (p.Leu301Phe) single nucleotide variant Likely pathogenic rs1057520014 GRCh38 Chromosome 5, 150073480: 150073480

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 CBL CSF2 FLT3 IL2 IL3 JAK2
2
Show member pathways
12.66 ABL1 CBL CSF2 FLT3 IL3 KIT
3 12.48 ABL1 CBL FLT3 IL2 IL3 JAK2
4
Show member pathways
12.47 CSF2 IL2 IL3 JAK2 MPL
5
Show member pathways
12.38 CBL CSF2 IL2 IL3
6 12.32 CBL IL2 IL3 JAK2 KIT MPL
7
Show member pathways
12.3 CBL FLT3 IL3 JAK2
8
Show member pathways
12.04 CBL IL3 JAK2 KIT
9
Show member pathways
12.01 CSF2 IL2 IL3 JAK2
10 11.89 ABL1 CBL FLT3 JAK2 KIT
11 11.77 CSF2 ETV6 FLT3 IL3 KMT2A RUNX1
12 11.76 ABL1 IL2 IL3 JAK2
13 11.72 CSF2 FLT3 IL3 KIT
14 11.66 IL2 KIT RUNX1
15
Show member pathways
11.62 CSF2 IL2 IL3
16 11.57 CSF2 FLT3 IL2 KIT
17 11.55 ABL1 IL2 WT1
18 11.4 CSF2 IL3 RUNX1
19 11.23 CSF2 ENG FLT3 IL2 IL3 KIT
20 11.11 CSF2 IL2 IL3
21 10.8 CBL KIT

GO Terms for Hematologic Cancer

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.88 ABL1 CSF2 JAK2 KIT
2 MAPK cascade GO:0000165 9.83 CSF2 IL2 IL3 JAK2 KIT
3 male gonad development GO:0008584 9.81 CBL KIT WT1
4 protein autophosphorylation GO:0046777 9.8 ABL1 FLT3 JAK2 KIT
5 positive regulation of cell proliferation GO:0008284 9.8 CSF2 FLT3 IL2 IL3 JAK2 KIT
6 regulation of hematopoietic stem cell differentiation GO:1902036 9.79 ABL1 KMT2A RUNX1
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 ABL1 IL3 JAK2
8 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.76 ABL1 FLT3 JAK2 KIT
9 hemopoiesis GO:0030097 9.72 FLT3 KIT RUNX1
10 regulation of regulatory T cell differentiation GO:0045589 9.63 IL2 RUNX1
11 peptidyl-tyrosine phosphorylation GO:0018108 9.63 ABL1 CSF2 FLT3 IL3 JAK2 KIT
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.62 CBL FLT3 JAK2 KIT
13 interleukin-6-mediated signaling pathway GO:0070102 9.61 CBL JAK2
14 negative regulation of cell-cell adhesion GO:0022408 9.61 ABL1 JAK2
15 mast cell degranulation GO:0043303 9.6 CBL KIT
16 hematopoietic stem cell proliferation GO:0071425 9.59 ETV6 RUNX1
17 dendritic cell differentiation GO:0097028 9.57 CSF2 FLT3
18 regulation of myeloid cell differentiation GO:0045637 9.56 CSF2 RUNX1
19 cytokine-mediated signaling pathway GO:0019221 9.56 CBL CSF2 FLT3 IL2 IL3 JAK2
20 negative regulation of heart contraction GO:0045822 9.54 IL2 JAK2
21 embryonic hemopoiesis GO:0035162 9.54 IL3 KIT KMT2A
22 regulation of cytokine-mediated signaling pathway GO:0001959 9.52 IL3 RUNX1
23 myeloid progenitor cell differentiation GO:0002318 9.51 FLT3 KIT
24 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.48 ENG KIT
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.1 CSF2 FLT3 IL2 IL3 JAK2 KIT
26 negative regulation of apoptotic process GO:0043066 10.02 CBL FLT3 IL2 KIT WT1
27 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 ENG ETV6 IL2 KMT2A MLLT10 NUP98

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.35 CSF2 IL2 IL3 JAK2 KIT
2 peptide hormone receptor binding GO:0051428 9.16 JAK2 PTHLH
3 protein tyrosine kinase activity GO:0004713 9.1 ABL1 CSF2 FLT3 IL3 JAK2 KIT

Sources for Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....